These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29512735)

  • 61. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
    AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
    Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
    Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Breast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapy.
    Moon HG; Han W; Ahn SK; Cho N; Moon WK; Im SA; Park IA; Noh DY
    Ann Surg; 2013 Jan; 257(1):133-7. PubMed ID: 22968080
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prognostic value of (99m)Tc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy.
    Sciuto R; Pasqualoni R; Bergomi S; Petrilli G; Vici P; Belli F; Botti C; Mottolese M; Maini CL
    J Nucl Med; 2002 Jun; 43(6):745-51. PubMed ID: 12050317
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer?
    Perez RO; Habr-Gama A; Pereira GV; Lynn PB; Alves PA; Proscurshim I; Rawet V; Gama-Rodrigues J
    Colorectal Dis; 2012 Jun; 14(6):714-20. PubMed ID: 22568644
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison of Breast MR Imaging with Molecular Breast Imaging in Breast Cancer Screening, Diagnosis, Staging, and Treatment Response Evaluation.
    Rauch GM; Adrada BE
    Magn Reson Imaging Clin N Am; 2018 May; 26(2):273-280. PubMed ID: 29622132
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer.
    Rouzier R; Pusztai L; Garbay JR; Delaloge S; Hunt KK; Hortobagyi GN; Berry D; Kuerer HM
    Cancer; 2006 Oct; 107(7):1459-66. PubMed ID: 16948128
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor.
    Yamane Y; Ishii G; Goto K; Kojima M; Nakao M; Shimada Y; Nishiwaki Y; Nagai K; Kohrogi H; Ochiai A
    J Thorac Oncol; 2010 Jan; 5(1):49-55. PubMed ID: 20035185
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer.
    Cockburn A; Yan J; Rahardja D; Euhus D; Peng Y; Fang Y; Rumnong Sarode V
    Hum Pathol; 2014 Feb; 45(2):249-58. PubMed ID: 24289969
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical imaging for the prediction of neoadjuvant chemotherapy response in breast cancer.
    Hayashi M; Yamamoto Y; Iwase H
    Chin Clin Oncol; 2020 Jun; 9(3):31. PubMed ID: 32594748
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Breast MRI for Evaluation of Response to Neoadjuvant Therapy.
    Reig B; Lewin AA; Du L; Heacock L; Toth HK; Heller SL; Gao Y; Moy L
    Radiographics; 2021; 41(3):665-679. PubMed ID: 33939542
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pathology after neoadjuvant treatment - How to assess residual disease.
    Viale G; Fusco N
    Breast; 2022 Mar; 62 Suppl 1(Suppl 1):S25-S28. PubMed ID: 34810049
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Downstream imaging following abnormal molecular breast imaging, lessons learned and suggestions for success.
    Maimone S; Hatcher KM; Tavana A; Robinson KA
    Clin Imaging; 2022 Dec; 92():44-51. PubMed ID: 36191470
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Monitoring Early Breast Cancer Response to Neoadjuvant Therapy Using H-Scan Ultrasound Imaging: Preliminary Preclinical Results.
    Khairalseed M; Javed K; Jashkaran G; Kim JW; Parker KJ; Hoyt K
    J Ultrasound Med; 2019 May; 38(5):1259-1268. PubMed ID: 30280391
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer using sparse logistic regression.
    Hu W
    Int J Bioinform Res Appl; 2013; 9(3):242-60. PubMed ID: 23649738
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dynamic characterization of breast cancer response to neoadjuvant therapy using biophysical metrics of spatial proliferation.
    Bowers HJ; Douglas E; Ansley K; Thomas A; Weis JA
    Sci Rep; 2022 Jul; 12(1):11718. PubMed ID: 35810187
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The Wavelia Microwave Breast Imaging system-tumour discriminating features and their clinical usefulness.
    Moloney BM; McAnena PF; Elwahab SM; Fasoula A; Duchesne L; Gil Cano JD; Glynn C; O'Connell A; Ennis R; Lowery AJ; Kerin MJ
    Br J Radiol; 2021 Dec; 94(1128):20210907. PubMed ID: 34581186
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The role of large-format histopathology in assessing subgross morphological prognostic parameters: a single institution report of 1000 consecutive breast cancer cases.
    Tot T
    Int J Breast Cancer; 2012; 2012():395415. PubMed ID: 23150828
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Multispectral Mueller polarimetric imaging detecting residual cancer and cancer regression after neoadjuvant treatment for colorectal carcinomas.
    Pierangelo A; Manhas S; Benali A; Fallet C; Totobenazara JL; Antonelli MR; Novikova T; Gayet B; De Martino A; Validire P
    J Biomed Opt; 2013 Apr; 18(4):046014. PubMed ID: 23612875
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The subgross morphology of breast carcinomas: a single-institution series of 2033 consecutive cases documented in large-format histology slides.
    Tot T; Gere M; Hofmeyer S; Bauer A; Pellas U
    Virchows Arch; 2020 Mar; 476(3):373-381. PubMed ID: 31410558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.